Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Kadletz, L; Heiduschka, G; Wolf, A; Haug-Lettenbichler, A; Poyntner, L; Primosch, T; Rogatsch, H; Formanek, M; Stadler, M; Kenner, L; Eckel, HE; Brunner, M.
Effect of postoperative radiotherapy in pT1pN1cM0 and pT2p/cN0cM0 oropharyngeal squamous cell carcinoma.
Laryngoscope. 2018; 128(5):1075-1082 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Wolf Axel

Dimensions Citations:

Plum Analytics:
Consulting of patients with oropharyngeal carcinoma, classified as pT1pN1cM0 and pT2p/cN0cM0, about postoperative radiotherapy is a precarious task as data are lacking. The aim of this study was to evaluate the effects of postoperative radiotherapy for patients with intermediate-stage oropharyngeal carcinoma. Multicentric retrospective study. This analysis was conducted at seven Austrian institutions and included data of patients treated between 2000 and 2012. A total of 81 patients with oropharyngeal squamous cell carcinoma were included, of whom 33 patients received postoperative radiotherapy. p16 status determined by immunohistochemistry was available in 68 patients. Median follow-up was 47.9 months. Postoperative radiotherapy showed no benefits in regard to overall survival (P = .701). In contrast, disease-free survival was significantly shortened in all patients without postoperative radiotherapy (P = .001). When dividing the cohort in dependence of p16, p16-positive patients did not benefit from postoperative radiotherapy regarding overall and disease-free survival (P = .934 and P = .102), whereas p16-negative patients showed improved disease-free survival after postoperative radiotherapy (P = .007). Multivariate analysis showed that outcome of postoperative radiotherapy is dependent on p16 status. In terms of disease-free survival, patients with p16-negative tumors may benefit from postoperative radiotherapy, whereas survival of p16-positive patients is good regardless of additional treatment. 4. Laryngoscope, 128:1075-1082, 2018. © 2017 The American Laryngological, Rhinological and Otological Society, Inc.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Austria -
Carcinoma, Squamous Cell - radiotherapy
Carcinoma, Squamous Cell - surgery
Cyclin-Dependent Kinase Inhibitor p16 - analysis
Female -
Humans -
Immunohistochemistry -
Male -
Middle Aged -
Neoplasm Staging -
Oropharyngeal Neoplasms - radiotherapy
Oropharyngeal Neoplasms - surgery
Retrospective Studies -
Survival Rate -
Treatment Outcome -

Find related publications in this database (Keywords)
Oropharyngeal carcinoma
adjuvant radiotherapy
postoperative radiotherapy
© Med Uni Graz Impressum